Veru Shifts Focus to Cardiometabolic Drugs, Divests FC2 Business

TL;DR

**VERU is a high-risk, high-reward biotech play, ditching its only commercial product to bet big on unproven obesity and cardiovascular drugs; proceed with extreme caution.**

AI Summary

VERU INC. (VERU) is a late clinical stage biopharmaceutical company focused on developing novel medicines for cardiometabolic and inflammatory diseases, as detailed in its 10-K filing for the fiscal year ended September 30, 2025. The company's primary drug candidates are enobosarm, an oral selective androgen receptor modulator (SARM) for obesity treatment, and sabizabulin, a microtubule disruptor for atherosclerotic cardiovascular disease. On December 30, 2024, Veru divested its FDA-approved commercial product, the FC2 Female Condom Business. The company executed a 1-for-10 reverse stock split on August 8, 2025, which adjusted its outstanding common stock and related equity instruments. Veru's strategy centers on the clinical development of enobosarm to augment fat loss and preserve muscle mass in patients using GLP-1 RA drugs for weight reduction, addressing the 20-50% lean mass loss observed with GLP-1 RAs. The company acknowledges the need for substantial capital to fund its drug development and commercialization efforts, and it currently has no commercial revenue, indicating a history of losses.

Why It Matters

Veru's strategic pivot away from its commercial FC2 Female Condom business, sold on December 30, 2024, to focus entirely on its drug pipeline, particularly enobosarm for obesity and sabizabulin for cardiovascular disease, marks a high-stakes transition. For investors, this means betting on the successful clinical development and regulatory approval of these novel compounds, a notoriously risky and capital-intensive endeavor in the biopharmaceutical sector. Employees will see their roles shift towards R&D and clinical trial management, while customers of the FC2 product will now rely on its new owner. The broader market will watch to see if Veru can carve out a niche in the competitive cardiometabolic space, especially with enobosarm targeting the significant muscle loss issue associated with popular GLP-1 RA obesity drugs.

Risk Assessment

Risk Level: high — Veru is a late clinical stage biopharmaceutical company with "no commercial revenue" and a "history of losses," as stated in the filing. The company's future hinges entirely on the successful, costly, and uncertain clinical development and regulatory approval of its drug candidates, enobosarm and sabizabulin, requiring "substantial capital" and facing significant competition.

Analyst Insight

Investors should approach VERU with extreme caution, recognizing it as a speculative biotech play. Monitor clinical trial progress for enobosarm and sabizabulin closely, as well as the company's ability to secure the "significant funding" needed to advance these drug candidates, as its financial viability depends on these factors.

Financial Highlights

debt To Equity

Not Disclosed

revenue

$0

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

N/A

Key Numbers

• $64.1 million — Aggregate market value of common stock held by non-affiliates (As of March 31, 2025, based on a $4.90 closing price per share.)
• 16,050,320 — Shares of common stock outstanding (As of December 12, 2025, after the 1-for-10 reverse stock split.)
• 1-for-10 — Reverse Stock Split ratio (Effected on August 8, 2025, to adjust common stock shares.)
• December 30, 2024 — Date of FC2 Business sale (Marks the divestiture of Veru's only commercial product.)
• 20-50% — Lean mass loss in GLP-1 RA trials (Percentage of total weight loss attributable to muscle, highlighting enobosarm's target market.)
• 41.5% — Older adults with obesity (According to CDC, indicating a large potential market for obesity treatments.)
• 34.4% — Obese patients over 60 with sarcopenic obesity (Percentage of patients at risk for critically low muscle mass with GLP-1 RAs.)
• $0.01 — Par value per share (Common stock par value, unchanged by the reverse stock split.)
• September 30, 2025 — Fiscal year end (Reporting period for this 10-K filing.)
• August 8, 2025 — Date of Reverse Stock Split (Key corporate action affecting share structure.)

Key Players & Entities

• VERU INC. (company) — Registrant
• enobosarm (drug) — Oral selective androgen receptor modulator (SARM) in development for obesity
• sabizabulin (drug) — Microtubule disruptor in development for atherosclerotic cardiovascular disease
• FC2 Female Condom (product) — FDA-approved commercial product sold on December 30, 2024
• Nasdaq Capital Market (regulator) — Exchange where VERU common stock is traded
• U.S. Food and Drug Administration (FDA) (regulator) — Regulatory authority for drug approvals
• The Wisconsin Pharmacal Company, Inc. (company) — Predecessor to Veru Inc.
• Aspen Park Pharmaceuticals, Inc. (company) — Company acquired by Veru on October 31, 2016
• Centers for Disease Control and Prevention (CDC) (regulator) — Source for obesity statistics
• $64.1 million (dollar_amount) — Aggregate market value of common stock held by non-affiliates as of March 31, 2025

FAQ

Risk Factors

• Lack of Commercial Revenue and History of Losses [high — financial]: Veru Inc. currently has no commercial revenue, relying entirely on its drug development pipeline. The company has a history of significant losses and requires substantial capital to fund its operations and clinical trials. This lack of revenue generation and dependence on external funding creates a high financial risk.
• Clinical Trial and Regulatory Approval Risks [high — regulatory]: The company's success hinges on the successful development and regulatory approval of its drug candidates, enobosarm and sabizabulin. Clinical trials are lengthy, expensive, and have a high failure rate. Failure to obtain FDA approval for either drug would severely impact the company's prospects.
• Competition in Obesity and Cardiovascular Disease Markets [medium — market]: Veru faces intense competition in the obesity market, particularly with the rise of GLP-1 RA drugs. While enobosarm aims to mitigate lean mass loss, it enters a crowded space. Similarly, the atherosclerotic cardiovascular disease market is highly competitive with numerous established therapies.
• Dependence on Future Financing [high — financial]: The company explicitly acknowledges the need for substantial capital to fund its drug development and commercialization efforts. Without consistent access to financing through equity offerings, debt, or partnerships, Veru may be unable to complete its clinical trials or bring its products to market.
• Divestiture of Commercial Product [medium — operational]: The divestiture of the FC2 Female Condom Business on December 30, 2024, removed Veru's only source of commercial revenue. This strategic shift intensifies the company's reliance on its unproven drug pipeline and increases operational risk associated with managing a purely R&D-focused entity.
• Impact of Reverse Stock Split [low — financial]: The 1-for-10 reverse stock split effected on August 8, 2025, reduced the number of outstanding shares. While intended to increase the stock price, such splits can sometimes be perceived negatively by investors and may not fundamentally alter the company's financial health or development risks.

Industry Context

Veru operates in the highly competitive biopharmaceutical sector, focusing on cardiometabolic and inflammatory diseases. The obesity market is rapidly expanding, driven by the success of GLP-1 receptor agonists, creating an opportunity for complementary therapies like enobosarm that address side effects such as lean mass loss. The cardiovascular disease space is mature, requiring novel approaches to gain market traction.

Regulatory Implications

Veru's future hinges on successful clinical trials and subsequent FDA approval for enobosarm and sabizabulin. The company faces significant regulatory hurdles, including demonstrating safety and efficacy, which are costly and time-consuming. Any delays or failures in the regulatory process pose a substantial risk to the company's viability.

What Investors Should Do

1. Monitor clinical trial progress and FDA communications closely.
2. Assess the company's cash burn rate and future financing needs.
3. Evaluate the competitive landscape for obesity treatments.
4. Consider the implications of the recent reverse stock split.

Key Dates

• 2025-09-30: Fiscal Year End — Marks the end of the reporting period for the 10-K filing, providing the latest financial and operational data.
• 2025-08-08: 1-for-10 Reverse Stock Split — Significantly altered the company's share structure, reducing the number of outstanding shares and increasing the per-share price.
• 2025-07-25: Shareholder Approval of Reverse Stock Split — Indicates shareholder consent for the capital restructuring measure.
• 2024-12-30: Sale of FC2 Female Condom Business — Divested the company's only commercial product, shifting focus entirely to drug development and eliminating existing revenue streams.
• 2025-03-31: Measurement Date for Market Capitalization — Used to calculate the aggregate market value of common stock held by non-affiliates ($64.1 million) based on a $4.90 closing price.
• 2025-12-12: Outstanding Shares Measurement — Reported 16,050,320 shares of common stock outstanding after the reverse stock split.

Glossary

Selective Androgen Receptor Modulator (SARM)

A class of compounds that bind to androgen receptors, designed to mimic the beneficial effects of androgens (like testosterone) while minimizing unwanted side effects. (Enobosarm, Veru's key obesity drug candidate, is a SARM, targeting fat loss and muscle preservation.)

Microtubule Disruptor

A type of drug that interferes with the function of microtubules, essential components of cell structure and division, often used in cancer therapy but also explored for inflammatory conditions. (Sabizabulin, Veru's cardiovascular drug candidate, is a microtubule disruptor.)

GLP-1 RA drugs

Glucagon-like peptide-1 receptor agonists, a class of medications primarily used for type 2 diabetes and weight management, known to cause significant weight loss. (Veru's enobosarm is positioned as a complementary therapy to GLP-1 RAs to mitigate lean muscle loss.)

Sarcopenic Obesity

A condition characterized by the coexistence of obesity and sarcopenia (age-related loss of muscle mass and strength). (Highlights a specific patient population (older adults) at high risk for muscle loss with obesity treatments, a target for enobosarm.)

Reverse Stock Split

A corporate action where a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (Veru executed a 1-for-10 reverse stock split on August 8, 2025, to adjust its share count and potentially increase its stock price.)

FC2 Business

Refers to the company's former commercial product, the FC2 Female Condom, which was divested on December 30, 2024. (Its sale marked a significant strategic shift for Veru, moving away from commercial products to focus solely on drug development.)

Year-Over-Year Comparison

This 10-K reflects a significant strategic shift from the prior year, marked by the divestiture of the FC2 Female Condom Business on December 30, 2024, eliminating its sole source of commercial revenue. Consequently, revenue figures are expected to be zero compared to any prior period with commercial sales. The company has also undergone a 1-for-10 reverse stock split on August 8, 2025, fundamentally altering its share structure. New risks related to the sole focus on drug development and the need for substantial future financing are now paramount.

Key Financial Figures

• $0.01 — ange on which registered Common stock, $0.01 par value VERU Nasdaq Capital Marke
• $4.90 — he registrant's common stock, which was $4.90. There were 16,050,320 shares of the r

Filing Documents

• veru20250930_10k.htm (10-K) — 1839KB
• ex_858443.htm (EX-21) — 6KB
• ex_858444.htm (EX-23.1) — 3KB
• ex_858446.htm (EX-31.1) — 9KB
• ex_858447.htm (EX-31.2) — 10KB
• ex_858448.htm (EX-32.1) — 9KB
• verupipelinesized_oct2025.jpg (GRAPHIC) — 96KB
• 0001437749-25-038089.txt ( ) — 9754KB
• veru-20250930.xsd (EX-101.SCH) — 82KB
• veru-20250930_cal.xml (EX-101.CAL) — 79KB
• veru-20250930_def.xml (EX-101.DEF) — 679KB
• veru-20250930_lab.xml (EX-101.LAB) — 552KB
• veru-20250930_pre.xml (EX-101.PRE) — 708KB
• veru20250930_10k_htm.xml (XML) — 1285KB

Business

Business 6 Item 1A.

Risk Factors

Risk Factors 21 Item 1B. Unresolved Staff Comments 48 Item 1C. Cybersecurity 48 Item 2.

Properties

Properties 49 Item 3.

Legal Proceedings

Legal Proceedings 49 Item 4. Mine Safety Disclosures 49 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 49 Item 6. Reserved 49 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 50 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 61 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 61 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 61 Item 9A.

Controls and Procedures

Controls and Procedures 61 Item 9B. Other Information 62 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 62 PART III Item 10. Directors, Executive Officers and Corporate Governance 63 Item 11.

Executive Compensation

Executive Compensation 63 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 63 Item 13. Certain Relationships and Related Transactions, and Director Independence 63 Item 14. Principal Accountant Fees and Services 63 PART IV Item 15. Exhibits and Financial Statement Schedules 64 Item 16. Form 10-K Summary 68

Signatures

Signatures 69 As used in this report, the terms "we," "us," "our," "Veru" and the "Company" mean Veru Inc. and its subsidiaries collectively, unless the context indicates another meaning, and the term "common stock" means shares of our common stock, par value of $0.01 per share. All trademarks, service marks or trade names appearing in this report are the property of their respective owners. We do not intend the use or display of other companies' trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of or by, any of these other companies. 2 Table of Contents

FORWARD LOOKING STATEMENTS

FORWARD LOOKING STATEMENTS Certain statements included in this Annual Report on Form 10-K which are not statements of historical fact are intended to be, and are hereby identified as, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our financial condition or business, our development and commercialization plans relating to our product candidates and products, including any potential development or commercialization of enobosarm as a drug candidate that preserves muscle mass and augments fat loss in patients receiving a glucagon-like peptide-1 receptor agonist ("GLP-1 RA") for greater amount and higher quality weight loss for the treatment of obesity and sabizabulin to treat cardiovascular atherosclerotic disease to reduce major cardiovascular events, future financial and operating results, plans, objectives, expectations and intentions, costs and expenses, royalty payments, outcome of litigation and other contingencies, financial condition, results of operations, liquidity, cost savings, our ability to continue as a going concern, objectives of management, business strategies, clinical trial timing, plans and results, the achievement of clinical and commercial milestones, the advancement of our technologies and our products and drug candidates, our intellectual property strategy and whether any products may be patented, and other statements that are not historical facts. Forward-looking statements can be identified by the use of forward-looking words or phrases such as "anticipate," "believe," "could," "expect," "intend," "may," "opportunity," "plan," "predict," "potential," "estimate," "should," "will," "would" or the negative of these terms or other words of similar meaning. These statements are based upon the Company's current plans and strategies and reflect the Company's current assessment of the risks and uncertainties related to its busi

Business

Item 1. Business Overview We are a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic and inflammatory diseases. Our drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator ("SARM"), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass. This activity leads to improved body composition and physical function with expected clinically meaningful incremental weight reduction versus GLP-1 RA monotherapy. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease. On December 30, 2024, the Company sold its FDA-approved commercial product, the FC2 Female Condom (Internal Condom), for the dual protection against unplanned pregnancy and sexually transmitted infections (the "FC2 Business"). A chart showing our current drug candidate pipeline as of the date of this report is below. This chart is based on our current plans and is subject to change. See "Forward Looking Statements." Company History Veru is a Wisconsin corporation that is the successor to The Wisconsin Pharmacal Company, Inc. ("Wisconsin Pharmacal"), a company which manufactured and marketed disparate specialty chemical and branded consumer products. Wisconsin Pharmacal was originally incorporated in 1971. In 1996, we completed a series of actions which resulted in our acquisition of worldwide rights to our first-generation female condom, the divestiture of Wisconsin Pharmacal's other businesses and the change of our name to "The Female Health Company." On October 31, 2016, we completed our acquisition of Aspen Park Pharmaceuticals, Inc. (the "APP Acquisition"), which transitioned us from a single product company selling FC2 to a biopharmaceutical company with

View Full Filing

View this 10-K filing on SEC EDGAR